%0 Journal Article
%T Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.
%A Stefanski HE
%A Kuxhausen M
%A Bo-Subait S
%A Kobusingye H
%A Mattila D
%A Schenfeld J
%A Sandschafer D
%A De Oliveira Brandao C
%A Burns LJ
%A Shaw BE
%A Pulsipher MA
%A Miller JP
%A Devine SM
%J Blood Adv
%V 8
%N 15
%D 2024 Aug 13
%M 38687368
%F 7.637
%R 10.1182/bloodadvances.2024012646
%X <B>UNASSIGNED: </B>Allogeneic hematopoietic cell transplantation is a life-saving procedure used to treat a variety of devastating diseases. It requires hematopoietic stem cells collected via filgrastim-mobilized peripheral blood stem cells (PBSCs) or bone marrow (BM) harvest from volunteer unrelated donors (URDs). There is a paucity of safety data regarding donors' long-term adverse events. This prospective, observational study combined PBSC donors enrolled in the NMDP Investigational New Drug trial and BM donors between 1 July 1999 and 30 September 2015. The primary objective was to describe the long-term incidence of myeloid malignancies. The secondary objectives included describing the long-term incidence of lymphoid malignancies, nonhematologic malignancies, autoimmune disorders, and thrombotic events. A total of 21 643 donors (14 530 PBSCs and 7123 BM) were included. The incidence rate of myeloid disorders per 100 000 person-years in donors of PBSCs was 2.53 (95% confidence interval [CI], 0.82-7.84) and in donors of BM, it was 4.13 (95% CI, 1.33-12.8). The incidence rate ratio of PBSCs/BM donors was 0.61 (95% CI, 0.12-3.03; P = .55). The incidence of other malignancies, autoimmunity, and thrombosis did not differ between the donor types. This comprehensive study of the long-term effects of filgrastim in URDs of PBSCs provides strong evidence that donors who receive filgrastim are not at an increased risk of these events compared with BM donors. It also provides reassurance to current donors undergoing stem cell mobilization as well as individuals considering joining stem cell registries, such as NMDP.